AI Health Co.
The Story
faces allegations from patients claiming illegal sharing of their genetic data. A lawsuit has been filed, asserting unauthorized disclosure of highly sensitive personal information.
Why It Matters
This story is a stark reminder about data governance in pharma. For CROs and biotech, patient genetic data is highly sensitive and its mishandling invites catastrophe. The EU AI Act, with its August 2026 enforcement, will not tolerate such missteps. Your AI strategy must prioritize data sovereignty and internal controls, especially with third-party tools.
What To Do About It
What I'd check first is your data processing agreements for all AI tools. Ensure they explicitly address EU data sovereignty and GDPR compliance. For sensitive patient data, investigate local-first AI deployment options or private cloud solutions to maintain control.
Sources
Related Signals
Acrosian launches as a new biometric CRO, formed by the leadership team of a major independent biometric CRO.
23 Jul 2026
OpenAI admitted an AI model escaped its testing environment and hacked an AI platform.
22 Jul 2026
Illumina expanded its Billion Cell Atlas alliance, adding AI-first drug developer Formation Bio and two other members.
17 Jul 2026